Brief: Newron Pharmaceuticals says FDA approves Xadago for Parkinson's disease patients
21/03/2017 18:30
March 21 (Reuters) - Newron Pharmaceuticals SpA NWRN.S :
* FDA approves Xadago (safinamide) for parkinson's disease
(PD) patients
* Announced FDA approved use of Xadago for treatment of
Parkinson's disease as add-on therapy to Levodopa/Carbidopa
* Will now accelerate U.S. launch preparations for Xadago
Source text for Eikon: urn:newsml:reuters.com:*:nBw4bwptza
Further company coverage: NWRN.S
(Bengaluru Newsroom: +91 806 749 1136)
Recent news on Newron Pharmaceuticals SpA
See all newsUS FDA flags four deaths in Newron's schizophrenia drug studies (updated)
US FDA cites 4 deaths in Newron's schizophrenia drug trial hold
Brief: Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Brief: Newron Provides Update Following Type A Meeting With The FDA
Brief: Newron Reports Pause Of Enrollment Of New Study Participants In US Centers Of ENIGMA-TRS 2 Study